Definitive Healthcare (DH) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue was $62.3 million, down 6% year-over-year but exceeded the high end of guidance, with new business growth and expanded customer relationships through upsell and cross-sell opportunities.

• Adjusted EBITDA was $17.5 million (28% margin), down 12% year-over-year, and adjusted net income improved to $12.6 million.

• Customer churn remained elevated, especially in life sciences, mainly due to downsells rather than full client losses.

• Leadership changes include a new Chief Customer Officer and incoming CFO effective June 2025.

• Focus remains on operational efficiency and innovation to position for market recovery in 2025.

Financial highlights

• Adjusted net income and non-GAAP EPS grew 18% and 19% year-over-year, respectively; adjusted EPS was $0.08 in Q4.

• Unlevered free cash flow was $72.5 million for the trailing 12 months, up 6% year-over-year.

• Adjusted gross profit was $50.3 million, down 10% year-over-year, with an 81% margin.

• Adjusted operating income was $15.8 million, down 14% year-over-year; margin was 25%.

• Q4 cash flow from operations was $8.1 million; full year was $58.2 million, up 41% year-over-year.

Outlook and guidance

• Q1 2025 revenue expected at $55.5–$57 million, down 10–13% year-over-year; adjusted EBITDA $10.5–$11.5 million (19–20% margin).

• Full-year 2025 revenue guidance is $230–$240 million, a 5–9% decline year-over-year; adjusted EBITDA $61–$65 million (26–28% margin).

• Adjusted net income for 2025 projected at $30–$34 million; adjusted net income per diluted share expected at $0.19–$0.22.

• Guidance assumes low to mid-80s net dollar retention and continued revenue pressure in H1, with improvement in H2.

• Guidance reflects uncertainty in renewal rates and sales productivity.